ArriVent BioPharma, Inc.

Nasdaq:AVBP

Pharmaceutical Preparations·NEWTOWN SQUARE, PA

CEO

Yao Zhengbin

CFO

Kung Winston

Financials

9 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	3/5/26	→
10-Q	Q3 2025	9/30/25	11/10/25	→
10-Q	Q2 2025	6/30/25	8/11/25	→
10-Q	Q1 2025	3/31/25	5/12/25	→
10-K	FY 2024	12/31/24	3/3/25	→
10-Q	Q3 2024	9/30/24	11/14/24	→
↓

Earnings Releases (8-K)

9 shown

Filed	Period
3/5/26	Q1 FY2026	→
11/10/25	Q4 FY2025	→
8/11/25	Q3 FY2025	→
5/12/25	Q2 FY2025	→
3/3/25	Q1 FY2025	→
11/14/24	Q4 FY2024	→
↓

News (8-K)

15 shown

Filed	Type	Description
9/9/25	Reg FD	Regulation FD Disclosure	→
7/21/25	Other	Other Events	→
7/2/25	Agreement	Entry into a Material Definitive Agreement	→
6/23/25	Reg FD	Regulation FD Disclosure	→
6/20/25	Vote	Submission of Matters to a Vote of Security Holders	→
4/28/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

12 shown

Filed	Form	Description
3/5/26	S-8	S-8	→
7/2/25	424B5	424B5	→
7/1/25	424B5	424B5	→
4/28/25	ARS	ARS	→
3/3/25	S-8	S-8	→
2/3/25	S-3ASR	S-3ASR	→
↓

Filing History(135 filings)

TypeDateAccessionPeriodSize

S-8

Mar 5, 2026

0001104659-26-024136FORM S-8

—

190.7 KB

10-K

Mar 5, 2026

0001104659-26-02412710-K

Dec 31, 2025

13.0 MB

8-K

Mar 5, 2026

0001104659-26-0241128-K

Mar 5, 2026

311.4 KB

SCHEDULE 13G/A

Mar 5, 2026

0001104659-26-023750

—

28.6 KB

SCHEDULE 13G/A

Feb 17, 2026

0002058093-26-000004

—

9.2 KB

SCHEDULE 13G/A

Feb 17, 2026

0000902664-26-001013

—

8.7 KB

Feb 4, 2026

0001104659-26-010478OWNERSHIP DOCUMENT

Feb 2, 2026

5.6 KB

Feb 4, 2026

0001104659-26-010477OWNERSHIP DOCUMENT

Feb 2, 2026

5.6 KB

Feb 4, 2026

0001104659-26-010473OWNERSHIP DOCUMENT

Feb 2, 2026

5.6 KB

Feb 4, 2026

0001104659-26-010472OWNERSHIP DOCUMENT

Feb 2, 2026

5.5 KB

Feb 4, 2026

0001104659-26-010471OWNERSHIP DOCUMENT

Feb 2, 2026

5.5 KB

Feb 3, 2026

0000902664-26-000675

Dec 10, 2025

9.6 KB

SCHEDULE 13G/A

Jan 30, 2026

0000102909-26-000090

—

7.0 KB

SCHEDULE 13G

Jan 21, 2026

0002012383-26-000643

—

10.7 KB

SCHEDULE 13G/A

Nov 14, 2025

0001214659-25-016716

—

13.8 KB

10-Q

Nov 10, 2025

0001104659-25-10884710-Q

Sep 30, 2025

5.9 MB

8-K

Nov 10, 2025

0001104659-25-1088398-K

Nov 10, 2025

352.9 KB

SCHEDULE 13G/A

Nov 5, 2025

0000315066-25-002677

—

11.4 KB

SCHEDULE 13G

Oct 30, 2025

0000102909-25-000025

—

6.1 KB

SCHEDULE 13G/A

Oct 17, 2025

0002012383-25-002500

—

10.8 KB

SCHEDULE 13G

Oct 15, 2025

0001104659-25-099728

—

7.7 KB

8-K

Sep 9, 2025

0001558370-25-0119548-K

Sep 9, 2025

196.3 KB

SCHEDULE 13G/A

Aug 14, 2025

0001415889-25-021943

—

7.4 KB

SCHEDULE 13D/A

Aug 13, 2025

0000947871-25-000764

—

33.0 KB

SCHEDULE 13G/A

Aug 13, 2025

0000919574-25-004712

—

16.8 KB

25 filings shown

ArriVent BioPharma, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(135 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/4/26	4	OWNERSHIP DOCUMENT	→
2/4/26	4	OWNERSHIP DOCUMENT	→
2/4/26	4	OWNERSHIP DOCUMENT	→
2/4/26	4	OWNERSHIP DOCUMENT	→
2/4/26	4	OWNERSHIP DOCUMENT	→
2/3/26	4	4	→
↓